Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension

Inclusion Criteria: * Individual is ≥18 years and ≤65 years old. * Primary hypertension. * Screen criteria: Individual who received a stable anti-hypertensive medication regimen including 2 or more anti-hypertensive medications of different classes prior to screening, and at the initial screening visit, he has an office systolic blood pressure(SBP)≥ 150mmHg, and ≤180mmHg, is entering the screening period after writing the informed consent. Individual is receiving a 4week standard dose of amlodipine besylate (Norvasc) and Losartan Potassium and Hydrochlorothiazide tablets (HYZAAR®), and has a SBP≥150mmHg and\<180mmHg at the second week after screening, and has an Ambulatory 24-hour daytime average systolic blood pressure monitoring ≥140mmHg and \<170mmHg at the fourth week after screening. Exclusion Criteria: * Secondary hypertension. * History of prior renal artery intervention including balloon angioplasty or stenting. * Renal artery stenosis (≥50%) in either renal artery. * Main renal arteries with \<4mm, or \>8mm in diameter. * Main renal arteries with \<20mm in length. * Estimated glomerular filtration rate (eGFR) of \<40 ml/(min•1.73m2). * History of Stroke or TIA within 6 months prior to screening period. * History of Acute coronary syndrome within 6 months prior to screening period. * Structural heart disease without receiving effective treatment; Coronary heart disease with β blockers; severe peripheral artery disease that affecting blood pressure measurement and other unqualified conditions evaluated by investigator. * Heart failure (NYHA classification Ⅲ-Ⅳ). * Coagulation disorders associated with significant bleeding tendency, and history of other blood system diseases. * History of cancer. * Type 1 diabetes mellitus; Type 2 diabetes mellitus with target organ injuring. * Acute or severe systemic inflammatory response syndrome. * Any other serious medical condition unqualified to participate in this study evaluated by investigator.